Equal-WT
WhaleScore 2.0
?
TRI Locum Partners is based out of New York. TRI Locum Partners is a hedge fund with 5 clients and discretionary assets under management (AUM) of $357,536,952 (Form ADV from 2024-03-28). Their last reported 13F filing for Q3 2024 included $417,406,489 in managed 13F securities
and a top 10 holdings concentration of 79.89%. TRI Locum Partners's largest holding is Pfizer, Inc with shares held of 1,732,935. Whalewisdom has at least 16 13F filings, and 2 13G filings
Business Description
Tri Locum offers advisory services and investment strategies to clients, subject to each client's investment objectives and guidelines. They may engage in any investment strategy and make any investment they deem appropriate, even if not explicitly described in their brochure. Their investment strategies are speculative and carry substantial risk, meaning clients should be prepared for potential capital loss. There is no guarantee that any client's investment objectives will be achieved.
Tri Locum and its affiliates are entitled to performance-based compensation, which may create incentives to recommend riskier investments. To mitigate this conflict, all investment decisions are made in accordance with Tri Locum's Investment Allocation Policy, designed to ensure fair and equitable treatment for all clients. Research and brokerage services obtained through client commissions may benefit all clients, not necessarily a specific client in any given instance. Commission rates are negotiable, and selecting brokers based on factors beyond commission rates may result in higher transaction costs.
Investment Strategy
The investment objective of the Funds is to generate risk-adjusted returns in all market and economic conditions by employing a long/short strategy that aims to capitalize on innovation in the healthcare sector, across biotechnology, pharmaceuticals, services, and medical devices. The Funds invest primarily in equity and equity-related securities of companies within the healthcare sector in the Americas, Asia and Europe.
The investment strategies pursued by the Funds are speculative and entail substantial risks. There can be no assurance that the investment objectives of any Client will be achieved. The Adviser has broad discretion in making investments for the Funds, which may include equities, equity-related securities, options and derivatives and other assets that may be affected by business, financial market or legal uncertainties. The value of the Funds’ portfolio may fluctuate as the general level of interest rates fluctuates.
Known Email Addresses
(Subscription Required)
Other Contact Information
(Subscription Required)
2024-09-30
Top Buys (13F)
| Name | % Change |
|---|---|
| PFE Pfizer, Inc | 7.79% |
| STVN Stevanato Group Spa | 6.33% |
| PCVX Vaxcyte, Inc | 5.28% |
| VRNA Verona Pharma Plc | 4.09% |
| NTRA Natera Inc | 3.34% |
2024-09-30
Top Sells (13F)
| Name | % Change |
|---|---|
| ASND Ascendis Pharma A/S | 7.85% |
| AMGN Amgen, Inc | 6.5% |
| REGN Regeneron Pharmaceut | 4.65% |
| AXSM Axsome Therapeutics | 4.26% |
| INSM Insmed Inc | 2.84% |
2024-09-30
13F Holdings Summary
| Name | $ Change |
|---|---|
| PFE Pfizer, Inc | 12.01% |
| TEVA Teva Pharmaceutical | 11.9% |
| NTRA Natera Inc | 9.65% |
| STVN Stevanato Group Spa | 8.95% |
| ARGX Argenx SE ADS ADR | 8.11% |
2024-09-30
13F Activity
| Market Value | $417m, Prior: $395m |
| Inflows (Outflows) as % of Total MV | (-3.4465)% |
| New Purchases | 2 stocks |
| Added To | 11 stocks |
| Sold out of | 7 stocks |
| Reduced holdings in | 6 stocks |
| Top 10 Holdings % | 79.89% |
| Turnover %[1] | 33.33% |
| Turnover Alt %[2] | 33.12% |
| Time Held Top 20 | 2.15 quarters |
| Time Held Top 10 | 0.7 quarters |
| Time Held All | 3.45 quarters |
[1]: Turnover is calculated by taking the # of new holdings (initial purchases) + the # of positions sold out of (not just reduced) divided by the total # of holdings for the quarter.
[2]: Alt Turnover is calculated by taking either the total MV of new purchases or the MV of securities sold, whichever is less, divided by the total MV of the fund.
2024-09-30
13F Sector Allocation Over Time
limited to past 4 quarters. Subscribe to see all available data
2024-09-30
Analysis
Top 20 equal-weighted holdings. Performance numbers calculated through 2024-09-30